Israel’s Teva expects FDA approval in 2017 for seven innovative treatments. They include for chronic migraine, multiple sclerosis, Huntington’s Disease and tardive dyskinesia (movement disorder).

http://www.globes.co.il/en/article-tevas-pipeline-shows-promise-1001177680